The present invention provides a compound of formula I;

This invention relates to a method of increasing testosterone levels and treating hypogonadism and related diseases with the aromatase inhibitor 4,4'-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile. The present invention further relates to a method of increasing testosterone levels and treating hypogonadism and related diseases with the aromatase inhibitor 4,4'-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile in a particular dosing regimen. The invention also relates to pharma...

The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.

FIELD: medicine pharmaceutics.SUBSTANCE: present invention refers to chemical-pharmaceutical industry and presents using (-)-(3aR4S7aR)-4-hydroxy-4-m-tolylethinyloctahydroindole-1-carboxylic acid methyl ester for treating preventing or arresting the development of dyskinesia caused by levodopa (L-dopa) in treating Parkinson's disease.EFFECT: invention refers to a pharmaceutical composition a kit and a foodstuff containing (-)-(3aR4S7aR)-4-hydroxy-4-m-tolylethinyloctahydroindole-1-carboxylic acid...

The invention provides a pharmaceutical combination comprising: a) a pyrimidylaminobenzamide compound and b) imatinib. and a method for treating or preventing a proliferative disease especially GIST using such a combination.

Abstract The invention relates to a certain oral dosage form providing absorption of the drug diclofenac in an ultrafast manner.

The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof wherein R1 R2 R3 R4 R6 A1 A2 X1 s and m are defined herein. The invention also relates to a method for manufacturing the compounds of the invention and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.